Quest Diagnostics raised and tightened its 2020 financial outlook on Thursday, citing sharper than expected recovery in its base business through August after routine test volumes took a big hit from lockdowns and stay-at-home orders earlier in the year.
Quest Diagnostics (NYSE:DGX) +2% expects FY20 GAAP EPS $7.42-$8.92 from prior guidance of $5.66-$7.66 -
PLEASANT PRAIRE, Wis., June 24, 2020 /PRNewswire/ -- Quest Products, LLLC. (Quest) today announced its acquisition of Summit Pharmaceuticals / Alliance Labs. Quest is a portfolio company of Promus Equity Partners (Promus).